The time is right for a new classification system for diabetes: Rationale and implications of the β-cell-centric classification schema

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 179-186

  Schwartz, Stanley S ^a,d   Epstein, Solomon ^b   Corkey, Barbara E ^c   Grant, Struan F A ^d   Gavin, James R ^e   Aguilar, Richard B ^f  

^a Main Line Health Heart Center   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Diabetes Nation ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

AUTOIMMUNE DISEASE; CELL STRESS; CLINICAL RESEARCH; CONSENSUS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG TARGETING; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNE DYSREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LATENT AUTOIMMUNE DIABETES OF ADULTS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERSONALIZED MEDICINE; PHENOTYPE; REVIEW; CLASSIFICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; PATHOLOGY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS;

EID: 84962061584     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1585     Document Type: Review

References (89)

1. Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. 24 October 2015 [Epub ahead of print]
2. Grant SFA, Hakonarson H, Schwartz S. Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocr Rev 2010; 31:183-193
3. Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010; 53:1250-1253
4. Redondo MJ. LADA: time for a new definition. Diabetes 2013;62:339-340
5. Basile KJ, Guy VC, Schwartz S, Grant SFA. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 2014;14:550
6. Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am 2015;99: 1-16
7. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endo-crinol Diabetes Obes 2015;22:277-282
8. Guy VC, Chesi A, Hawa M, et al. The role of GWAS-implicated type 1 and type 2 diabetes loci in the pathogenesis of latent autoimmune diabetes in adults (LADA) (Abstract) Diabetes 2015;64(Suppl. 1):A80
9. Corkey BE. Diabetes: have we got it all wrong? Insulin hypersecretion and food addi tives: cause of obesity and type 2 diabetes? Diabetes Care 2012;35:2432-2437
10. Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev 2012;28 (Suppl. 2):40-46
11. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014;37:210-216
12. Lebovitz HE. Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6: 326-334
13. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opin Phar-macother 2015;16:2331-2341
14. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483
15. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol 2014;8:1011-1017
16. Tafuri KS, Godil MA, Lane AH, Wilson TA. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013;5:236-239
17. Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014;99:E876-E880
18. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10: 376-386
19. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-275
20. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and met-formin: a proof-of-concept study. Diabetes Care 2010;33:1509-1515
21. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-298
22. Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66-84
23. Schwartz SS, DeFronzo RA, Umpierrez GE. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. Postgrad Med 2015;127:251-257
24. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117-2128
25. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419
26. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-136
27. Anik A, Çatli G, Abaci A, Böber E. Maturity-onsetdiabetesof the young (MODY): an update. J Pediatr Endocrinol Metab 2015;28:251-263
28. Longo N, Wang Y, Pasquali M. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 1999;84: 2623-2629
29. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
30. Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic pheno-types: systematic review and meta-analysis of observational evidence. Eur J Epidemiol 2015; 30:599-614
31. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
32. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007;56: 1189-1197
33. Subauste A, Gianani R, Chang AM et al. Islet autoimmunity identifies a unique pattern of impaired pancreatic β-cell function, markedly reduced pancreatic beta cell mass and insulin resistance in clinically diagnosed type 2 diabetes. PLoS One 2014;9:e106537
34. Oslowski CM, Hara T, O'Sullivan-Murphy B, et al. Thioredoxin-interacting protein mediates ER stress-induced b cell death through initiation of the inflammasome. Cell Metab 2012;16: 265-273
35. Chaudhuri A, Ghanim H, Vora M, et al. Ex-enatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012;97:198-207
36. Makdissi A, Ghanim H, Vora M, et al. Sita-gliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012;97:3333-3341
37. Kahn SE, Cooper ME, Del Prato S. Patho-physiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068-1083
38. Allin KH, Nielsen T, Pedersen O. Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 2015;172:R167-R177
39. Tai N, Wong FS, Wen L. The role of gut mi-crobiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord 2015;16:55-65
40. Carvalho BM, Saad MJ Influence of gut mi-crobiota on subclinical inflammation and insulin resistance. Mediators Inflamm 2013;2013: 986734
41. Del Prato S. Role of glucotoxicity and lipo-toxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009;26:1185-1192
42. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-506
43. Iwakura T, Fujimoto S, Kagimoto S, et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000; 271:422-428
44. Reimer MK, Holst JJ, Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717-727
45. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sita-gliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-1704
46. Chen J, Couto FM, Minn AH, Shalev A. Ex-enatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006;346:1067-1074
47. Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011;54:1098-1108
48. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014;13:465-476
49. Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes melli-tus. Nat Rev Endocrinol 2014;10:229-242
50. Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995; 96:132-140
51. Straub RH. Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Res Ther 2014; 16(Suppl. 2):S4
52. Simmons AL, Schlezinger JJ, Corkey BE. What are we putting in our food that is making us fat? Food additives, contaminants, and other putative contributors to obesity. Curr Obes Rep 2014;3:273-285
53. Erion KA, Berdan CA, Burritt NE, Corkey BE, Deeney JT. Chronic exposure to excess nutrients left-shifts the concentration dependence of glucose-stimulated insulin secretion in pancreatic beta cells. J Biol Chem 2015;290:16191-16201
54. Halban PA, Polonsky KS, Bowden DW, et al. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751-1758
55. Stähli BE, Gebhard C, Tardif JC. Lipid effects and cardiovascular disease risk associated with glucose-lowering medications. Curr Cardiol Rep 2015;17:608
56. Chevalier N, Fénichel P. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab 2015;41: 107-115
57. Escobedo G, López-Ortiz E, Torres-Castro I. Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance. Rev Invest Clin 2014;66:450-459
58. Biswas SK, Mohtarin S, Mudi SR, et al. Relationship of soluble RAGE with insulin resistance and beta cell function during development of type 2 diabetes mellitus. J Diabetes Res 2015; 2015:150325
59. Raciti GA, Longo M, Parrillo L, et al. Understanding type 2 diabetes: from genetics to epigenetics. Acta Diabetol 2015;52:821-827
60. Zhao M, Wang Z, Yung S, Lu Q. Epigenetic dynamics in immunity and autoimmunity. Int J Biochem Cell Biol 2015;67:65-74
61. Schlaich M, Straznicky N, Lambert E, Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol 2015;3: 148-157
62. Coomans CP, van den Berg SA, Lucassen EA, et al. The suprachiasmatic nucleus controls cir-cadian energy metabolism and hepatic insulin sensitivity. Diabetes 2013;62:1102-1108
63. Mandrup-Poulsen T. IAPP boosts islet macrophage IL-1 in type 2 diabetes. Nat Immunol 2010;11:881-883
64. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003;52:1-8
65. Gottlieb PA. What defines disease in an age of genetics and biomarkers? Curr Opin Endocri-nol Diabetes Obes 2015;22:296-299
66. Groop L, Storm P, Rosengren A. Can genetics improve precision of therapy in diabetes? Trends Endocrinol Metab 2014;25:440-443
67. Zhou K, Donnelly L, Yang J, et al.; Wellcome Trust Case Control Consortium 2. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014;2:481-487
68. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 2014; 383:1084-1094
69. Wherrett DK, Chiang JL, Delamater AM, et al.; Type 1 Diabetes TrialNet Study Group. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care 2015;38:1975-1985
70. Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction. Endocr Pract 2012;18: 342-350
71. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-442
72. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21: 438-447
73. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S127-S138
74. Federal Drug Administration. Code of Federal Regulations Title 21. Sec. 310.517: Labeling for oral hypoglycemic drugs of the sulfonylurea class, 49 FR 14331, 11 April 1984. Available from http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=310.517. Accessed 20 September 2015
75. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonyl-ureas and metformin. Diabetologia 2006;49: 930-936
76. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17:753-759
77. Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012;14:1-4
78. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
79. Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr 2011;3:10
80. Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer-systematic review and meta-analysis of observational studies. Curr Drug Saf 2013;8:333-348
81. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253-2261
82. Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 2015;95:727-748
83. Kelly CT, Mansoor J, Dohm GL, Chapman WH 3rd, Pender JR 4th, Pories WJ. Hyperinsuli-nemic syndrome: the metabolic syndrome is broader than you think. Surgery 2014;156: 405-411
84. Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014;63: 2232-2243
85. Muntoni S, Muntoni S. Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab 2011;58:25-36
86. Riddle M, Frias J, Zhang B, et al. Pramlin-tide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007;30:2794-2799
87. Garber AJ, King AB, Del Prato S, et al.; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-1507
88. Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes. Poster presented at the 48th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2012, Berlin, Germany
89. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356: 1517-1526